ARMP
Armata Pharmaceuticals, Inc.
Biotechnology
Market Cap$331M
5Y Perf.+123.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ARMP vs BNTX
Revenue, margins, valuation, and 5-year total return — side by side.
BNTX
BioNTech SE
Biotechnology
Market Cap$23.52B
5Y Perf.+90.0%
ARMP vs BNTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ARMP | BNTX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $331M | $23.52B |
| Revenue (TTM) | $5M | $2.86B |
| Net Income (TTM) | $-47M | $-1.13B |
| Gross Margin | 70.5% | 77.7% |
| Operating Margin | -6.6% | -45.9% |
| Total Debt | $127M | $267M |
| Cash & Equiv. | $9M | $7.67B |
ARMP vs BNTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ARMP
BNTX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | 100 | 223.1 | +123.1% |
| BioNTech SE (BNTX) | 100 | 190.0 | +90.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARMP vs BNTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BNTX leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Armata Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ARMP
Armata Pharmaceuticals, Inc.
The Growth Play
ARMP is the clearest fit if your priority is growth exposure.
- Rev growth 14.2%, EPS growth 72.6%, 3Y rev CAGR 5.0%
- 14.2% revenue growth vs BNTX's 0.2%
- +5.7% vs BNTX's +0.2%
Best for: growth exposure
BNTX
BioNTech SE
The Income Pick
BNTX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.14
- 5.7% 10Y total return vs ARMP's -97.4%
- Lower volatility, beta 1.14, Low D/E 1.4%, current ratio 7.54x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARMP | 14.2% revenue growth vs BNTX's 0.2% |
| Quality / Margins | BNTX | -39.6% margin vs ARMP's -9.3% |
| Stability / Safety | BNTX | Beta 1.14 vs ARMP's 1.44 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ARMP | +5.7% vs BNTX's +0.2% |
| Efficiency (ROA) | BNTX | -5.3% ROA vs ARMP's -54.5%, ROIC -4.3% vs -44.2% |
ARMP vs BNTX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ARMP vs BNTX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBNTXLAGGINGARMP
ARMPArmata Pharmaceutical…
1leads
BNTXBioNTech SE
5leads
6 Total Categories
CATEGORYLEADERvs ARMPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BNTX6/6
Valuation MetricsMultiples, price ratios, and targets
BNTX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BNTX5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ARMP5/6
Risk & VolatilityBeta, volatility, and downside exposure
BNTX2/2
Analyst OutlookRatings, price targets, and dividends
BNTX1/1
Income & Cash Flow (Last 12 Months)
BNTX leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BNTX is the larger business by revenue, generating $2.9B annually — 566.2x ARMP's $5M. Profitability is closely matched — net margins range from -39.6% (BNTX) to -9.3% (ARMP). On growth, BNTX holds the edge at -24.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ARMPArmata Pharmaceut… | BNTXBioNTech SE |
|---|---|---|
| RevenueTrailing 12 months | $5M | $2.9B |
| EBITDAEarnings before interest/tax | -$32M | -$931M |
| Net IncomeAfter-tax profit | -$47M | -$1.1B |
| Free Cash FlowCash after capex | -$27M | $277M |
| Gross MarginGross profit ÷ Revenue | +70.5% | +77.7% |
| Operating MarginEBIT ÷ Revenue | -6.6% | -45.9% |
| Net MarginNet income ÷ Revenue | -9.3% | -39.6% |
| FCF MarginFCF ÷ Revenue | -5.4% | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -61.0% | -24.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.9% | -2.1% |
BNTX leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
BNTX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ARMPArmata Pharmaceut… | BNTXBioNTech SE |
|---|---|---|
| Market CapShares × price | $331M | $23.5B |
| Enterprise ValueMkt cap + debt − cash | $449M | $14.8B |
| Trailing P/EPrice ÷ TTM EPS | -17.49x | -17.55x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 64.06x | 7.26x |
| Price / BookPrice ÷ Book value/share | — | 1.00x |
| Price / FCFMarket cap ÷ FCF | — | 74.19x |
BNTX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
BNTX leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), BNTX scores 4/9 vs ARMP's 2/9, reflecting mixed financial health.
| Metric | ARMPArmata Pharmaceut… | BNTXBioNTech SE |
|---|---|---|
| ROE (TTM)Return on equity | — | -6.0% |
| ROA (TTM)Return on assets | -54.5% | -5.3% |
| ROICReturn on invested capital | -44.2% | -4.3% |
| ROCEReturn on capital employed | -70.7% | -3.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | — | 0.01x |
| Net DebtTotal debt minus cash | $117M | -$7.4B |
| Cash & Equiv.Liquid assets | $9M | $7.7B |
| Total DebtShort + long-term debt | $127M | $267M |
| Interest CoverageEBIT ÷ Interest expense | -2.12x | -62.15x |
BNTX leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ARMP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARMP five years ago would be worth $21,942 today (with dividends reinvested), compared to $5,178 for BNTX. Over the past 12 months, ARMP leads with a +567.9% total return vs BNTX's +0.2%. The 3-year compound annual growth rate (CAGR) favors ARMP at 89.7% vs BNTX's -4.9% — a key indicator of consistent wealth creation.
| Metric | ARMPArmata Pharmaceut… | BNTXBioNTech SE |
|---|---|---|
| YTD ReturnYear-to-date | +39.5% | -3.8% |
| 1-Year ReturnPast 12 months | +567.9% | +0.2% |
| 3-Year ReturnCumulative with dividends | +582.8% | -13.9% |
| 5-Year ReturnCumulative with dividends | +119.4% | -48.2% |
| 10-Year ReturnCumulative with dividends | -97.4% | +568.1% |
| CAGR (3Y)Annualised 3-year return | +89.7% | -4.9% |
ARMP leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
BNTX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BNTX is the less volatile stock with a 1.14 beta — it tends to amplify market swings less than ARMP's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BNTX currently trades 75.0% from its 52-week high vs ARMP's 56.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARMPArmata Pharmaceut… | BNTXBioNTech SE |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.05x |
| 52-Week HighHighest price in past year | $16.34 | $124.00 |
| 52-Week LowLowest price in past year | $1.17 | $79.52 |
| % of 52W HighCurrent price vs 52-week peak | +56.0% | +75.0% |
| RSI (14)Momentum oscillator 0–100 | 42.2 | 43.3 |
| Avg Volume (50D)Average daily shares traded | 50K | 1.2M |
BNTX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
BNTX leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates ARMP as "Buy" and BNTX as "Buy". Consensus price targets imply 63.9% upside for ARMP (target: $15) vs 49.9% for BNTX (target: $139).
| Metric | ARMPArmata Pharmaceut… | BNTXBioNTech SE |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | $139.44 |
| # AnalystsCovering analysts | 4 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
BNTX leads this category, winning 1 of 1 comparable metric.
Key Takeaway
BNTX leads in 5 of 6 categories (Income & Cash Flow, Valuation Metrics). ARMP leads in 1 (Total Returns).
Best OverallBioNTech SE (BNTX)Leads 5 of 6 categories
Loading custom metrics...
ARMP vs BNTX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ARMP or BNTX a better buy right now?
For growth investors, Armata Pharmaceuticals, Inc.
(ARMP) is the stronger pick with 14. 2% revenue growth year-over-year, versus 0. 2% for BioNTech SE (BNTX). Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARMP or BNTX?
Over the past 5 years, Armata Pharmaceuticals, Inc.
(ARMP) delivered a total return of +119. 4%, compared to -48. 2% for BioNTech SE (BNTX). Over 10 years, the gap is even starker: BNTX returned +575. 8% versus ARMP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARMP or BNTX?
By beta (market sensitivity over 5 years), BioNTech SE (BNTX) is the lower-risk stock at 1.
05β versus Armata Pharmaceuticals, Inc. 's 1. 24β — meaning ARMP is approximately 18% more volatile than BNTX relative to the S&P 500.
04Which is growing faster — ARMP or BNTX?
By revenue growth (latest reported year), Armata Pharmaceuticals, Inc.
(ARMP) is pulling ahead at 14. 2% versus 0. 2% for BioNTech SE (BNTX). On earnings-per-share growth, the picture is similar: Armata Pharmaceuticals, Inc. grew EPS 72. 6% year-over-year, compared to -62. 8% for BioNTech SE. Over a 3-year CAGR, ARMP leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ARMP or BNTX?
BioNTech SE (BNTX) is the more profitable company, earning -39.
6% net margin versus -365. 6% for Armata Pharmaceuticals, Inc. — meaning it keeps -39. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BNTX leads at -22. 6% versus -820. 2% for ARMP. At the gross margin level — before operating expenses — BNTX leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ARMP or BNTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ARMP or BNTX better for a retirement portfolio?
For long-horizon retirement investors, BioNTech SE (BNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
05), +575. 8% 10Y return). Both have compounded well over 10 years (BNTX: +575. 8%, ARMP: -97. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ARMP and BNTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ARMP: -61.0% · BNTX: -24.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.